Today we have shortlisted seven U.S. healthcare penny stocks that have delivered a decent total return (>30.0%) year-to-date. According to the Bloomberg estimated 12-month target price, these stocks are expected to yield strong price returns (>100.0%). During the past one month, all of the stocks have registered price gains with daily average trading volumes in excess of 100,000.
| Company Name |
Ticker |
Exchange |
Market Cap |
Last Price |
Average Volume |
Price Change (1-Month) |
Total Return YTD |
Target Price* |
Upside Potential |
|
Celator Pharmaceuticals Inc |
CPXX |
NASDAQ |
100.7 |
2.99 |
472,747 |
67.0% |
52.6% |
11.00 |
267.9% |
|
Anthera Pharmaceuticals Inc |
ANTH |
NASDAQ |
57.3 |
2.50 |
613,631 |
49.7% |
58.2% |
8.00 |
220.0% |
|
Alexza Pharmaceuticals Inc |
ALXA |
NASDAQ |
41.5 |
2.14 |
190,785 |
40.8% |
43.6% |
6.25 |
192.1% |
|
Athersys Inc |
ATHX |
NASDAQ |
163.6 |
2.11 |
793,202 |
49.6% |
33.5% |
5.39 |
155.3% |
|
GenVec Inc |
GNVC |
NASDAQ |
59.2 |
3.43 |
112,315 |
64.1% |
64.9% |
8.50 |
147.8% |
|
Apricus Biosciences Inc |
APRI |
NASDAQ |
59.0 |
1.33 |
384,091 |
34.3% |
33.0% |
2.83 |
113.0% |
|
Fibrocell Science Inc |
FCSC |
NASDAQ |
156.9 |
3.84 |
126,466 |
61.3% |
48.3% |
8.13 |
111.6% |
Source: Bloomberg
* 12-month target price
Company Description
Celator Pharmaceuticals Inc (NASDAQ: CPXX)
Celator Pharmaceuticals, Inc. develops and produces advance biopharmaceutical products. The company researches and distributes therapies to treat cancer, leukemia, and small cell lung cancer through the proper regulation of chemotherapy. Celator Pharmaceuticals serves customers throughout the United States and Canada.
Anthera Pharmaceuticals Inc (NASDAQ: ANTH)
Anthera Pharmaceuticals Inc. is a biopharmaceutical company. The company is focused on developing and commercializing anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases.
Alexza Pharmaceuticals Inc (NASDAQ: ALXA)
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of proprietary products for the treatment of acute and intermittent conditions.
Athersys Inc (NASDAQ: ATHX)
Athersys Incorporated is a clinical-stage biotechnology company. The company develops allogeneic stem cell products that focus on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions.
GenVec Inc (NASDAQ: GNVC)
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. The company specializes in the treatment of cancers, including pancreatic cancer, esophageal cancer, rectal cancer, and head and neck cancer. The company is also involved in studies involving hearing loss and balance disorders. GenVec also develops vaccines for infectious diseases.
Apricus Biosciences Inc (NASDAQ: APRI)
Apricus Biosciences Inc. is a bio-technology company. The company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer.
Fibrocell Science Inc (NASDAQ: FCSC)
Fibrocell Science, Inc. is a biotechnology company that develops skin and tissue rejuvenation technologies. The company’s process multiplies the patient’s collagen producing cells and returns them to the patient’s skin to treat damage caused by aging, the sun, acne, and burns.
